scholarly journals SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19

2021 ◽  
Author(s):  
Supriya Ravichandran ◽  
Juanjie Tang ◽  
Gabrielle Grubbs ◽  
Youri Lee ◽  
Sara Pourhashemi ◽  
...  
Keyword(s):  
2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Gary Kwok Cheong Lee ◽  
Dorothee Bienzle ◽  
Stefan Matthias Keller ◽  
Mei-Hua Hwang ◽  
Nikos Darzentas ◽  
...  

Abstract Background Lymphocytic neoplasms with frequent reactive lymphocytes are uncommonly reported in dogs, and can pose a diagnostic challenge. Different diagnostic modalities such as cytology, flow cytometry, histopathology, immunohistochemistry, and clonality testing, are sometimes required for a diagnosis. This report illustrates the value of using a multi-modal diagnostic approach to decipher a complex lymphocytic tumor, and introduces immune repertoire sequencing as a diagnostic adjunct. Case presentation A 10-month-old Great Dane was referred for marked ascites. Cytologic analysis of abdominal fluid and hepatic aspirates revealed a mixed lymphocyte population including numerous large lymphocytes, yielding a diagnosis of lymphoma. Flow cytometrically, abdominal fluid lymphocytes were highly positive for CD4, CD5, CD18, CD45, and MHC II, consistent with T cell lymphoma. Due to a rapidly deteriorating clinical condition, the dog was euthanized. Post mortem histologic evaluation showed effacement of the liver by aggregates of B cells surrounded by T cells, suggestive of hepatic T cell-rich large B cell lymphoma. Immune repertoire sequencing confirmed the presence of clonal B cells in the liver but not the abdominal fluid, whereas reactive T cells with shared, polyclonal immune repertoires were found in both locations. Conclusions T cell-rich large B cell lymphoma is a rare neoplasm in dogs that may be challenging to diagnose and classify due to mixed lymphocyte populations. In this case, the results of histopathology, immunohistochemistry and immune repertoire sequencing were most consistent with a hepatic B cell neoplasm and reactive T cells exfoliating into the abdominal fluid. Immune repertoire sequencing was helpful in delineating neoplastic from reactive lymphocytes and characterizing repertoire overlap in both compartments. The potential pitfalls of equating atypical cytomorphology and monotypic marker expression in neoplasia are highlighted.


2017 ◽  
Vol 18 (1) ◽  
Author(s):  
Anke Fähnrich ◽  
Moritz Krebbel ◽  
Normann Decker ◽  
Martin Leucker ◽  
Felix D. Lange ◽  
...  

2021 ◽  
Vol 79 ◽  
pp. S641
Author(s):  
R. Benítez Dorta ◽  
K. Yu ◽  
M. Sirota ◽  
N. Malats ◽  
S. Pineda

2013 ◽  
Vol 9 (3) ◽  
pp. 125-126 ◽  
Author(s):  
Heinz Wiendl ◽  
Bernd Kieseier
Keyword(s):  

2018 ◽  
Vol 36 (11) ◽  
pp. 1035-1036 ◽  
Author(s):  
Dmitriy A Bolotin ◽  
Stanislav Poslavsky ◽  
Alexey N Davydov ◽  
Dmitriy M Chudakov

Author(s):  
Richard J. Cote ◽  
Donna M. Morrissey ◽  
Alan N. Houghton ◽  
Herbert F. Oettgen ◽  
Lloyd J. Old

2019 ◽  
Author(s):  
Arash Nabbi ◽  
Natalie Jäger ◽  
Sumedha Sudhaman ◽  
Pengbo Sun ◽  
S. Y. Cindy Yang ◽  
...  

2014 ◽  
Author(s):  
Fan Gao ◽  
Kai Wang

Background As one of the genetic mechanisms for adaptive immunity, V(D)J recombination generates an enormous repertoire of T-cell receptors (TCRs). With the development of high-throughput sequencing techniques, systematic exploration of V(D)J recombination becomes possible. Multiplex PCR method has been previously developed to assay immune repertoire, however the usage of primer pools has inherent bias in target amplification. In our study, we developed a ligation-anchored PCR method to unbiasedly amplify the repertoire. Results By utilizing a universal primer paired with a single primer targeting the conserved constant region, we amplified TCR-beta (TRB) variable regions from total RNA extracted from blood. Next-generation sequencing libraries were then prepared for Illumina HiSeq 2500 sequencer, which provided 151 bp read length to cover the entire V(D)J recombination region. We evaluated this approach on blood samples from patients with malignant and benign meningiomas. Mapping of sequencing data showed 64% to 91% of mapped TCRV-containing reads belong to TRB subtype. An increased usage of TRBV29-1 was observed in malignant meningiomas. Also distinct signatures were identified from CDR3 sequence logos, with predominant subset as 42 nt for benign and 45 nt for malignant samples, respectively. Conclusions In summary, we report an integrative approach to monitor immune repertoire in a systematic manner.


2020 ◽  
Vol 52 (2) ◽  
pp. 530-542 ◽  
Author(s):  
Bum-Sup Jang ◽  
In Ah Kim

PurposeCombination of radiotherapy and immune checkpoint blockade such as programmed death- 1 (PD-1) or programmed death-ligand 1 (PD-L1) blockade is being actively tested in clinical trial. We aimed to identify a subset of patients that could potentially benefit from this strategy using The Cancer Genome Atlas (TCGA) dataset for glioblastoma (GBM).Materials and MethodsA total of 399 cases were clustered into radiosensitive versus radioresistant (RR) groups based on a radiosensitivity gene signature and were also stratified as PD-L1 high versus PD-L1 low groups by expression of CD274 mRNA. Differential and integrated analyses with expression and methylation data were performed. CIBERSORT was used to enumerate the immune repertoire that resulted from transcriptome profiles.ResultsWe identified a subset of GBM, PD-L1-high-RR group which showed worse survival compared to others. In PD-L1-high-RR, differentially expressed genes (DEG) were highly enriched for immune response and mapped into activation of phosphoinositide 3-kinase–AKT and mitogen-activated protein kinase (MAPK) signaling pathways. Integration of DEG and differentially methylated region identified that the kinase MAP3K8-involved in T-cell receptor signaling was upregulated and BAI1, a factor which inhibits angiogenesis, was silenced. CIBERSORT showed that a higher infiltration of the immune repertoire, which included M2 macrophages and regulatory T cells.ConclusionTaken together, PD-L1-high-RR group could potentially benefit from radiotherapy combined with PD-1/PD-L1 blockade and angiogenesis inhibition.


Sign in / Sign up

Export Citation Format

Share Document